PAHC PE Ratio & Valuation,Is PAHC Overvalued

PAHC Relative Valuation

PAHC's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, PAHC is overvalued; if below, it's undervalued.

Historical Valuation

Phibro Animal Health Corp (PAHC) is now in the Fair zone, suggesting that its current forward PE ratio of 14.59 is considered Fairly compared with the five-year average of 13.68. The fair price of Phibro Animal Health Corp (PAHC) is between 30.16 to 44.27 according to relative valuation methord.

Relative Value

Fair Zone

30.16-44.27

Current Price：40.81

Fair

14.59

9.76

EV/EBITDA

Phibro Animal Health Corp. (PAHC) has a current EV/EBITDA of 9.76. The 5-year average EV/EBITDA is 9.14. The thresholds are as follows: Strongly Undervalued below 5.89, Undervalued between 5.89 and 7.51, Fairly Valued between 10.76 and 7.51, Overvalued between 10.76 and 12.38, and Strongly Overvalued above 12.38. The current Forward EV/EBITDA of 9.76 falls within the Historic Trend Line -Fairly Valued range.

11.73

EV/EBIT

Phibro Animal Health Corp. (PAHC) has a current EV/EBIT of 11.73. The 5-year average EV/EBIT is 12.27. The thresholds are as follows: Strongly Undervalued below 8.72, Undervalued between 8.72 and 10.50, Fairly Valued between 14.04 and 10.50, Overvalued between 14.04 and 15.82, and Strongly Overvalued above 15.82. The current Forward EV/EBIT of 11.73 falls within the Historic Trend Line -Fairly Valued range.

1.10

Phibro Animal Health Corp. (PAHC) has a current PS of 1.10. The 5-year average PS is 0.77. The thresholds are as follows: Strongly Undervalued below 0.30, Undervalued between 0.30 and 0.54, Fairly Valued between 1.01 and 0.54, Overvalued between 1.01 and 1.25, and Strongly Overvalued above 1.25. The current Forward PS of 1.10 falls within the Overvalued range.

11.46

P/OCF

Phibro Animal Health Corp. (PAHC) has a current P/OCF of 11.46. The 5-year average P/OCF is 4.51. The thresholds are as follows: Strongly Undervalued below -5.10, Undervalued between -5.10 and -0.29, Fairly Valued between 9.32 and -0.29, Overvalued between 9.32 and 14.12, and Strongly Overvalued above 14.12. The current Forward P/OCF of 11.46 falls within the Overvalued range.

17.63

P/FCF

Phibro Animal Health Corp. (PAHC) has a current P/FCF of 17.63. The 5-year average P/FCF is 8.85. The thresholds are as follows: Strongly Undervalued below -6.68, Undervalued between -6.68 and 1.08, Fairly Valued between 16.62 and 1.08, Overvalued between 16.62 and 24.38, and Strongly Overvalued above 24.38. The current Forward P/FCF of 17.63 falls within the Overvalued range.

Phibro Animal Health Corp (PAHC) has a current Price-to-Book (P/B) ratio of 5.29. Compared to its 3-year average P/B ratio of 2.97 , the current P/B ratio is approximately 78.47% higher. Relative to its 5-year average P/B ratio of 3.20, the current P/B ratio is about 65.19% higher. Phibro Animal Health Corp (PAHC) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of 0.80%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of 0.72% , the current FCF yield is about -100.00% lower.

5.29

P/B

Median3y

2.97

Median5y

3.20

2.11

FCF Yield

Median3y

0.80

Median5y

0.72

Competitors Valuation Multiple

The average P/S ratio for PAHC's competitors is 0.00, providing a benchmark for relative valuation. Phibro Animal Health Corp Corp (PAHC) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 39.73%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of PAHC increased by 94.64% over the past 1 year. The primary factor behind the change was an increase in Margin Expansion from 2.68 to 7.29.

The secondary factor is the Revenue Growth, contributed 39.73%to the performance.

Overall, the performance of PAHC in the past 1 year is driven by Margin Expansion. Which is more sustainable.

39.73%

260.43M → 363.89M

Revenue Growth

172.01%

2.68 → 7.29

Margin Expansion

-117.10%

-142.47 → 24.36

P/E Change

94.64%

20.90 → 40.67

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Phibro Animal Health Corp (PAHC) currently overvalued or undervalued?

What is Phibro Animal Health Corp (PAHC) fair value?

PAHC's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Phibro Animal Health Corp (PAHC) is between 30.16 to 44.27 according to relative valuation methord.

How does PAHC's valuation metrics compare to the industry average?

What is the current P/B ratio for Phibro Animal Health Corp (PAHC) as of Dec 16 2025?

As of Dec 16 2025, Phibro Animal Health Corp (PAHC) has a P/B ratio of 5.29. This indicates that the market values PAHC at 5.29 times its book value.

What is the current FCF Yield for Phibro Animal Health Corp (PAHC) as of Dec 16 2025?

As of Dec 16 2025, Phibro Animal Health Corp (PAHC) has a FCF Yield of 0.00%. This means that for every dollar of Phibro Animal Health Corp’s market capitalization, the company generates 0.00 cents in free cash flow.

What is the current Forward P/E ratio for Phibro Animal Health Corp (PAHC) as of Dec 16 2025?

As of Dec 16 2025, Phibro Animal Health Corp (PAHC) has a Forward P/E ratio of 14.59. This means the market is willing to pay $14.59 for every dollar of Phibro Animal Health Corp’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Phibro Animal Health Corp (PAHC) as of Dec 16 2025?

As of Dec 16 2025, Phibro Animal Health Corp (PAHC) has a Forward P/S ratio of 0.00. This means the market is valuing PAHC at $0.00 for every dollar of expected revenue over the next 12 months.

PAHC Valuation